Biora Therapeutics, Inc. BIORQ
0.00 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.0001 52-week range 0.22
- YTD
- -99.95%
- 1 year
- -99.95%
News
globenewswire.com Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Testing in advanced animal model planned in Q4 f or smaller, 00-size BioJet device with largest capacity of any ingestible injectable
globenewswire.com Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and…
globenewswire.com Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive…
globenewswire.com Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 Expanded collaborations to support rapid testing in advanced animal models in Q4 2024
globenewswire.com Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in…
seekingalpha.com Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
globenewswire.com Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan
globenewswire.com Biora Therapeutics Announces Funding Agreement with Existing Investors SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with…
globenewswire.com Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and…
globenewswire.com Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024 SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical…
globenewswire.com Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024 Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.
seekingalpha.com Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive…
globenewswire.com Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented…
globenewswire.com Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and…
globenewswire.com Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024 SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data…
globenewswire.com Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600 Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc.…
globenewswire.com Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent…
globenewswire.com Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no…
globenewswire.com Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously…
globenewswire.com Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into…